# An Evaluation of the Safety of CSF-1 in Presbyopic Subjects

> **NCT05393895** · PHASE3 · COMPLETED · sponsor: **Orasis Pharmaceuticals Ltd.** · enrollment: 178 (actual)

## Conditions studied

- Presbyopia

## Interventions

- **DRUG:** CSF-1
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05393895
- **Lead sponsor:** Orasis Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-22
- **Primary completion:** 2022-12-01
- **Final completion:** 2022-12-01
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393895, "An Evaluation of the Safety of CSF-1 in Presbyopic Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05393895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*